07.09.2026
Hemo Bioengineering is pleased to highlight the CE MDR approval of its AsprAX Aspiration Catheter and CerebrAX Stent Retriever, achieved in 2025. This regulatory milestone marked an important step in the expansion of Hemo's neurovascular portfolio and its continued development in the European market.
The AsprAX Aspiration Catheter is designed for neurovascular procedures, including mechanical thrombectomy for the treatment of acute ischemic stroke. Available in a comprehensive range of sizes from 0.035" to 0.088", the AsprAX family provides physicians with a broad selection of catheter options to address different anatomical and procedural requirements.
Complementing the aspiration platform, the CerebrAX Stent Retriever is designed for mechanical thrombectomy and is available in a range of sizes to support the treatment of different target vessels and thrombus locations. Together, AsprAX and CerebrAX form part of Hemo Bioengineering's expanding portfolio of solutions for endovascular stroke treatment.
The CE MDR approval of both product families reflects Hemo Bioengineering's continued commitment to developing and commercialising innovative neuro-interventional technologies that address the needs of physicians and patients.
At MEDICA 2026, Hemo Bioengineering looks forward to presenting its neurovascular portfolio to healthcare professionals, distributors and potential business partners from across Europe and other international markets.
Visitors are welcome to connect with the Hemo team at MEDICA 2026 to learn more about AsprAX, CerebrAX and opportunities for distribution and commercial collaboration.